Campath 1H

Thalassemia

Baylor College of MedicineN/ADormant

D

17/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 2/ 100
Competitive Position: 89/ 100

Competitive context

22 Active assets in the Thalassemia cohort.

Asset / Sponsor	Phase	Rating
Deferasirox Novartis Pharmaceuticals	Phase 4	BBB
Fludarabine Memorial Sloan Kettering Cancer Center	Phase 2/3	BB
Hydroxyurea Riphah International University	Phase 4	BB
Ppsv23 Fakultas Kedokteran Universitas Indonesia	Phase 4	BB
Etavopivat Novo Nordisk A/S	Phase 3	BB

View all 50 →

Same molecule, other indications

Campath 1H is also rated in:

leukemiaDormant

C

Indicative ·

35 / 100

myelodysplastic syndromeDormant

C

Indicative ·

35 / 100

myeloproliferative neoplasmDormant

D

Indicative ·

31 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.